{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T16:37:17Z","timestamp":1793205437252,"version":"4.5.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"FCT\/MCTES, Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia and Minist\u00e9rio da Ci\u00eancia, Tecnologia e Ensino Superior","award":["2020.04613.BD"],"award-info":[{"award-number":["2020.04613.BD"]}]},{"name":"FCT\/MCTES, Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia and Minist\u00e9rio da Ci\u00eancia, Tecnologia e Ensino Superior","award":["2022.05718.PTDC, 0.54499\/LA\/P\/0008\/2020, 10.54499\/UIDP\/50006\/2020, 10.54499\/UIDB\/50006\/2020"],"award-info":[{"award-number":["2022.05718.PTDC, 0.54499\/LA\/P\/0008\/2020, 10.54499\/UIDP\/50006\/2020, 10.54499\/UIDB\/50006\/2020"]}]},{"name":"FCT\/MCTES, Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia and Minist\u00e9rio da Ci\u00eancia, Tecnologia e Ensino Superior","award":["2020.06020.BD"],"award-info":[{"award-number":["2020.06020.BD"]}]},{"name":"FCT\/MCTES, Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia and Minist\u00e9rio da Ci\u00eancia, Tecnologia e Ensino Superior","award":["2022.05718.PTDC, 0.54499\/LA\/P\/0008\/2020, 10.54499\/UIDP\/50006\/2020, 10.54499\/UIDB\/50006\/2020"],"award-info":[{"award-number":["2022.05718.PTDC, 0.54499\/LA\/P\/0008\/2020, 10.54499\/UIDP\/50006\/2020, 10.54499\/UIDB\/50006\/2020"]}]},{"name":"FCT\/MCTES, Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia and Minist\u00e9rio da Ci\u00eancia, Tecnologia e Ensino Superior","award":["2022.05718.PTDC, 0.54499\/LA\/P\/0008\/2020, 10.54499\/UIDP\/50006\/2020, 10.54499\/UIDB\/50006\/2020"],"award-info":[{"award-number":["2022.05718.PTDC, 0.54499\/LA\/P\/0008\/2020, 10.54499\/UIDP\/50006\/2020, 10.54499\/UIDB\/50006\/2020"]}]},{"name":"FCT\/MCTES, Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia and Minist\u00e9rio da Ci\u00eancia, Tecnologia e Ensino Superior","award":["2022.05718.PTDC, 0.54499\/LA\/P\/0008\/2020, 10.54499\/UIDP\/50006\/2020, 10.54499\/UIDB\/50006\/2020"],"award-info":[{"award-number":["2022.05718.PTDC, 0.54499\/LA\/P\/0008\/2020, 10.54499\/UIDP\/50006\/2020, 10.54499\/UIDB\/50006\/2020"]}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana Ricerca sul Cancro","doi-asserted-by":"crossref","award":["AIRC; IG No 288801"],"award-info":[{"award-number":["AIRC; IG No 288801"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana Ricerca sul Cancro","doi-asserted-by":"crossref","award":["AIRC; IG No 288801"],"award-info":[{"award-number":["AIRC; IG No 288801"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Cancer Institute","award":["NHI; HHSN26100008"],"award-info":[{"award-number":["NHI; HHSN26100008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Pancreatic ductal adenocarcinoma (PDAC) is among the cancer types with poorest prognosis and survival rates primarily due to resistance to standard-of-care therapies, including gemcitabine (GEM) and olaparib. Particularly, wild-type (wt)BRCA tumours, the most prevalent in PDAC, are more resistant to DNA-targeting agents like olaparib, restraining their clinical application. Recently, we disclosed a monoterpene indole alkaloid derivative (BBIT20) as a new inhibitor of homologous recombination (HR) DNA repair with anticancer activity in breast and ovarian cancer. Since inhibition of DNA repair enhances the sensitivity of cancer cells to chemotherapy, we aimed to investigate the anticancer potential of BBIT20 against PDAC, particularly carrying wtBRCA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In vitro and in vivo PDAC models, particularly human cell lines (including GEM-resistant PDAC cells), patient-derived organoids and xenograft mice of PDAC were used to evaluate the anticancer potential of BBIT20, alone and in combination with GEM or olaparib. Disruption of the BRCA1-BARD1 interaction by BBIT20 was assessed by co-immunoprecipitation, immunofluorescence and yeast two-hybrid assay.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The potent antiproliferative activity of BBIT20, superior to olaparib, was demonstrated in PDAC cells regardless of BRCA status, by inducing cell cycle arrest, apoptosis, and DNA damage, while downregulating HR. The disruption of DNA double-strand breaks repair by BBIT20 was further reinforced by non-homologous end joining (NHEJ) suppression. The inhibition of BRCA1-BARD1 heterodimer by BBIT20 was demonstrated in PDAC cells and confirmed in a yeast two-hybrid assay. In GEM-resistant PDAC cells, BBIT20 showed potent antiproliferative, anti-migratory and anti-invasive activity, overcoming GEM resistance by inhibiting the multidrug resistance P-glycoprotein, upregulating the intracellular GEM-transporter ENT1, and downregulating GEM resistance-related microRNA-20a and GEM metabolism enzymes as RRM1\/2. Furthermore, BBIT20 did not induce resistance in PDAC cells. It inhibited the growth of patient-derived PDAC organoids, by inducing apoptosis, repressing HR, and potentiating olaparib and GEM cytotoxicity. The enhancement of olaparib antitumor activity by BBIT20 was confirmed in xenograft mice of PDAC. Notably, it hindered tumour growth and liver metastasis formation, improving survival of orthotopic xenograft mice of PDAC. Furthermore, its potential as a stroma-targeting agent, reducing fibrotic extracellular matrix and overcoming desmoplasia, associated with an enhancement of immune cell response by depleting PD-L1 expression in tumour tissues, renders BBIT20 even more appealing for combination therapy, particularly with immunotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>These findings underscore the great potential of BBIT20 as a novel multifaceted anticancer drug candidate for PDAC treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13046-025-03389-5","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T10:25:22Z","timestamp":1745490322000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A first-in-class inhibitor of homologous recombination DNA repair counteracts tumour growth, metastasis and therapeutic resistance in pancreatic cancer"],"prefix":"10.1186","volume":"44","author":[{"given":"Juliana","family":"Calheiros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipa","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Morais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Reis","family":"Moura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Fiorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silva","family":"Mulhovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana Q.","family":"Aguiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ricardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria In\u00eas","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00edlia","family":"Domingues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia A.","family":"Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Corbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Jos\u00e9 U.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00edlia","family":"Saraiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"3389_CR1","doi-asserted-by":"publisher","first-page":"188914","DOI":"10.1016\/j.bbcan.2023.188914","volume":"1878","author":"J Calheiros","year":"2023","unstructured":"Calheiros J, Corbo V, Saraiva L. Overcoming therapeutic resistance in pancreatic cancer: emerging opportunities by targeting BRCAs and p53. Biochim Biophys Acta Rev Cancer. 2023;1878:188914.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"3389_CR2","doi-asserted-by":"publisher","first-page":"e1000267","DOI":"10.1371\/journal.pmed.1000267","volume":"7","author":"S Gillen","year":"2010","unstructured":"Gillen S, Schuster T, Meyer Zum B\u00fcschenfelde C, Friess H, Kleeff J. Preoperative\/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7:e1000267.","journal-title":"PLoS Med"},{"key":"3389_CR3","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nrclinonc.2013.66","volume":"10","author":"J Werner","year":"2013","unstructured":"Werner J, Combs SE, Springfeld C, Hartwig W, Hackert T, B\u00fcchler MW. Advanced-stage pancreatic cancer: therapy options. Nat Rev Clin Oncol. 2013;10:323\u201333.","journal-title":"Nat Rev Clin Oncol"},{"key":"3389_CR4","doi-asserted-by":"publisher","unstructured":"Orth M, Metzger P, Gerum S, Mayerle J, Schneider G, Belka C et al. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiation Oncology [Internet]. 2019;14:141. Available from: https:\/\/doi.org\/10.1186\/s13014-019-1345-6","DOI":"10.1186\/s13014-019-1345-6"},{"key":"3389_CR5","doi-asserted-by":"crossref","unstructured":"Manji GA, Olive KP, Saenger YM, Oberstein P. Current and Emerging Therapies in Metastatic Pancreatic Cancer. Clinical Cancer Research. 2017;23:1670-1678.","DOI":"10.1158\/1078-0432.CCR-16-2319"},{"key":"3389_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1177\/1758834014564775","volume":"7","author":"A Teague","year":"2015","unstructured":"Teague A, Lim K-H, Wang-Gillam A. Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. Ther Adv Med Oncol. 2015;7:68\u201384.","journal-title":"Ther Adv Med Oncol"},{"key":"3389_CR7","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris 3rd","year":"1997","unstructured":"Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403\u201313.","journal-title":"J Clin Oncol"},{"key":"3389_CR8","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325.","journal-title":"N Engl J Med"},{"key":"3389_CR9","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703.","journal-title":"N Engl J Med"},{"key":"3389_CR10","doi-asserted-by":"publisher","first-page":"C540","DOI":"10.1152\/ajpcell.00331.2022","volume":"324","author":"AK Beutel","year":"2023","unstructured":"Beutel AK, Halbrook CJ. Barriers and opportunities for gemcitabine in pancreatic cancer therapy. Am J Physiol Cell Physiol. 2023;324:C540\u201352.","journal-title":"Am J Physiol Cell Physiol"},{"key":"3389_CR11","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1101\/gad.275776.115","volume":"30","author":"H Ying","year":"2016","unstructured":"Ying H, Dey P, Yao W, Kimmelman AC, Draetta GF, Maitra A, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2016;30:355\u201385.","journal-title":"Genes Dev"},{"key":"3389_CR12","doi-asserted-by":"crossref","unstructured":"Lai E, Ziranu P, Spanu D, Dubois M, Pretta A, Tolu S et al. BRCA-mutant pancreatic ductal adenocarcinoma. Br J Cancer. 2021.","DOI":"10.1038\/s41416-021-01469-9"},{"key":"3389_CR13","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1038\/bjc.2014.418","volume":"111","author":"T Golan","year":"2014","unstructured":"Golan T, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer. 2014;111:1132\u20138.","journal-title":"Br J Cancer"},{"key":"3389_CR14","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.jamcollsurg.2017.12.021","volume":"226","author":"AB Blair","year":"2018","unstructured":"Blair AB, Groot VP, Gemenetzis G, Wei J, Cameron JL, Weiss MJ, et al. BRCA1\/BRCA2 germline mutation carriers and sporadic pancreatic ductal adenocarcinoma. J Am Coll Surg. 2018;226:630\u2013e6371.","journal-title":"J Am Coll Surg"},{"key":"3389_CR15","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.molonc.2011.07.001","volume":"5","author":"T Helleday","year":"2011","unstructured":"Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol. 2011;5:387\u201393.","journal-title":"Mol Oncol"},{"key":"3389_CR16","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/annonc\/mdu581","volume":"26","author":"J Bendell","year":"2015","unstructured":"Bendell J, O\u2019Reilly EM, Middleton MR, Chau I, Hochster H, Fielding A, et al. Phase I study of Olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced\/metastatic pancreatic cancer. Ann Oncol. 2015;26:804\u201311.","journal-title":"Ann Oncol"},{"key":"3389_CR17","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1002\/cncr.31218","volume":"124","author":"EM O\u2019Reilly","year":"2018","unstructured":"O\u2019Reilly EM, Lee JW, Lowery MA, Capanu M, Stadler ZK, Moore MJ, et al. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. Cancer. 2018;124:1374\u201382.","journal-title":"Cancer"},{"key":"3389_CR18","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","volume":"33","author":"B Kaufman","year":"2015","unstructured":"Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balma\u00f1a J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. J Clin Oncol. 2015;33:244\u201350.","journal-title":"J Clin Oncol"},{"key":"3389_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejca.2017.11.004","volume":"89","author":"MA Lowery","year":"2018","unstructured":"Lowery MA, Kelsen DP, Capanu M, Smith SC, Lee JW, Stadler ZK, et al. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. Eur J Cancer. 2018;89:19\u201326.","journal-title":"Eur J Cancer"},{"key":"3389_CR20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance Olaparib for germline BRCA-Mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317\u201327.","journal-title":"N Engl J Med"},{"key":"3389_CR21","doi-asserted-by":"crossref","unstructured":"Pant S, Maitra A, Yap TA. PARP inhibition \u2014 opportunities in pancreatic cancer. Nat Rev Clin Oncol. 2019;16.","DOI":"10.1038\/s41571-019-0257-6"},{"key":"3389_CR22","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s41416-023-02326-7","volume":"129","author":"D Bhamidipati","year":"2023","unstructured":"Bhamidipati D, Haro-Silerio JI, Yap TA, Ngoi N. PARP inhibitors: enhancing efficacy through rational combinations. Br J Cancer. 2023;129:904\u201316.","journal-title":"Br J Cancer"},{"key":"3389_CR23","doi-asserted-by":"publisher","first-page":"688","DOI":"10.20892\/j.issn.2095-3941.2019.0252","volume":"16","author":"F Qui\u00f1onero","year":"2019","unstructured":"Qui\u00f1onero F, Mesas C, Doello K, Cabeza L, Perazzoli G, Jimenez-Luna C, et al. The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview. Cancer Biol Med. 2019;16:688\u201399.","journal-title":"Cancer Biol Med"},{"key":"3389_CR24","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1111\/bph.15506","volume":"178","author":"L Raimundo","year":"2021","unstructured":"Raimundo L, Paterna A, Calheiros J, Ribeiro J, Cardoso DSP, Piga I, et al. BBIT20 inhibits homologous DNA repair with disruption of the BRCA1\u2013BARD1 interaction in breast and ovarian cancer. Br J Pharmacol. 2021;178:3627\u201347.","journal-title":"Br J Pharmacol"},{"key":"3389_CR25","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1016\/j.bmcl.2015.06.084","volume":"25","author":"A Paterna","year":"2015","unstructured":"Paterna A, Borralho PM, Gomes SE, Mulhovo S, Rodrigues CMP, Ferreira M-JU. Monoterpene Indole alkaloid hydrazone derivatives with apoptosis inducing activity in human HCT116 colon and HepG2 liver carcinoma cells. Bioorg Med Chem Lett. 2015;25:3556\u20139.","journal-title":"Bioorg Med Chem Lett"},{"key":"3389_CR26","doi-asserted-by":"publisher","first-page":"837503","DOI":"10.3389\/fphar.2022.837503","volume":"13","author":"A Ragone","year":"2022","unstructured":"Ragone A, Salzillo A, Spina A, Naviglio S, Sapio L. Integrating Gemcitabine-Based therapy with adiporon enhances growth Inhibition in human PDAC cell lines. Front Pharmacol. 2022;13:837503.","journal-title":"Front Pharmacol"},{"key":"3389_CR27","doi-asserted-by":"crossref","unstructured":"Raimundo L, Espadinha M, Soares J, Loureiro JB, Alves MG, Santos MMM et al. Improving anticancer activity towards colon cancer cells with a new p53-activating agent. Br J Pharmacol [Internet]. 2018 [cited 2020 Feb 26];175:3947\u201362. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30076608","DOI":"10.1111\/bph.14468"},{"key":"3389_CR28","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676\u201382.","journal-title":"Nat Methods"},{"key":"3389_CR29","doi-asserted-by":"publisher","first-page":"e1448","DOI":"10.1371\/journal.pone.0001448","volume":"3","author":"CB Bennett","year":"2008","unstructured":"Bennett CB, Westmoreland TJ, Verrier CS, Blanchette CAB, Sabin TL, Phatnani HP, et al. Yeast screens identify the RNA polymerase II CTD and SPT5 as relevant targets of BRCA1 interaction. PLoS ONE. 2008;3:e1448.","journal-title":"PLoS ONE"},{"key":"3389_CR30","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nsmb.3236","volume":"23","author":"RM Densham","year":"2016","unstructured":"Densham RM, Garvin AJ, Stone HR, Strachan J, Baldock RA, Daza-Martin M, et al. Human BRCA1\u2013BARD1 ubiquitin ligase activity counteracts chromatin barriers to DNA resection. Nat Struct Mol Biol. 2016;23:647\u201355.","journal-title":"Nat Struct Mol Biol"},{"key":"3389_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13287-023-03250-6","volume":"14","author":"SR Moura","year":"2023","unstructured":"Moura SR, Freitas J, Ribeiro-Machado C, Lopes J, Neves N, Canh\u00e3o H, et al. Long non-coding RNA H19 regulates matrisome signature and impacts cell behavior on MSC-engineered extracellular matrices. Stem Cell Res Ther. 2023;14:37.","journal-title":"Stem Cell Res Ther"},{"key":"3389_CR32","doi-asserted-by":"publisher","first-page":"115303","DOI":"10.1016\/j.bone.2020.115303","volume":"134","author":"SR Moura","year":"2020","unstructured":"Moura SR, Bras JP, Freitas J, Os\u00f3rio H, Barbosa MA, Santos SG, et al. miR-99a in bone homeostasis: regulating osteogenic lineage commitment and osteoclast differentiation. Bone. 2020;134:115303.","journal-title":"Bone"},{"key":"3389_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27\u201355.","journal-title":"Adv Enzyme Regul"},{"key":"3389_CR34","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1373\/clinchem.2008.112797","volume":"55","author":"SA Bustin","year":"2009","unstructured":"Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative Real-Time PCR experiments. Clin Chem. 2009;55:611\u201322.","journal-title":"Clin Chem"},{"key":"3389_CR35","doi-asserted-by":"crossref","unstructured":"Boj SF, Hwang C-I, Baker LA, Chio IIC, Engle DD, Corbo V et al. Organoid models of human and mouse ductal pancreatic cancer. Cell [Internet]. 2014\/12\/31. 2015;160:324\u201338. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25557080","DOI":"10.1016\/j.cell.2014.12.021"},{"key":"3389_CR36","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1038\/s41467-024-45753-7","volume":"15","author":"B Adem","year":"2024","unstructured":"Adem B, Bastos N, Ruivo CF, Sousa-Alves S, Dias C, Vieira PF, et al. Exosomes define a local and systemic communication network in healthy pancreas and pancreatic ductal adenocarcinoma. Nat Commun. 2024;15:1496.","journal-title":"Nat Commun"},{"key":"3389_CR37","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1136\/gutjnl-2021-324994","volume":"71","author":"CF Ruivo","year":"2022","unstructured":"Ruivo CF, Bastos N, Adem B, Batista I, Duraes C, Melo CA, et al. Extracellular vesicles from pancreatic cancer stem cells lead an intratumor communication network (EVNet) to fuel tumour progression. Gut. 2022;71:2043\u201368.","journal-title":"Gut"},{"key":"3389_CR38","doi-asserted-by":"crossref","unstructured":"Soares J, Espadinha M, Raimundo L, Ramos H, Gomes AS, Gomes S et al. DIMP53-1: A novel small-molecule dual inhibitor of p53-MDM2\/X interactions with multifunctional p53-dependent anticancer properties. Mol Oncol [Internet]. 2017 [cited 2020 Feb 26];11:612\u201327. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28296148","DOI":"10.1002\/1878-0261.12051"},{"key":"3389_CR39","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fern\u00e1ndez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7:16878.","journal-title":"Sci Rep"},{"key":"3389_CR40","doi-asserted-by":"publisher","first-page":"102416","DOI":"10.1016\/j.mex.2023.102416","volume":"11","author":"N Baidoo","year":"2023","unstructured":"Baidoo N, Sanger GJ, Belai A. Histochemical and biochemical analysis of collagen content in formalin-fixed, paraffin embedded colonic samples. MethodsX. 2023;11:102416.","journal-title":"MethodsX"},{"key":"3389_CR41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1756-8722-5-15","volume":"5","author":"DZ Chang","year":"2012","unstructured":"Chang DZ, Ma Y, Ji B, Liu Y, Hwu P, Abbruzzese JL, et al. Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. J Hematol Oncol. 2012;5:15.","journal-title":"J Hematol Oncol"},{"key":"3389_CR42","doi-asserted-by":"publisher","first-page":"13089","DOI":"10.1080\/21655979.2022.2078940","volume":"13","author":"C Zhou","year":"2022","unstructured":"Zhou C, Wang L, Hu W, Tang L, Zhang P, Gao Y, et al. CDC25C is a prognostic biomarker and correlated with mitochondrial homeostasis in pancreatic adenocarcinoma. Bioengineered. 2022;13:13089\u2013107.","journal-title":"Bioengineered"},{"key":"3389_CR43","doi-asserted-by":"publisher","first-page":"164","DOI":"10.5306\/wjco.v2.i3.164","volume":"2","author":"B-B Liu","year":"2011","unstructured":"Liu B-B, Wang W-H. Survivin and pancreatic cancer. World J Clin Oncol. 2011;2:164\u20138.","journal-title":"World J Clin Oncol"},{"key":"3389_CR44","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/1476-4598-9-169","volume":"9","author":"J Yu","year":"2010","unstructured":"Yu J, Ohuchida K, Mizumoto K, Sato N, Kayashima T, Fujita H, et al. MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. Mol Cancer. 2010;9:169.","journal-title":"Mol Cancer"},{"key":"3389_CR45","doi-asserted-by":"publisher","first-page":"215","DOI":"10.4166\/kjg.2015.66.4.215","volume":"66","author":"WH Paik","year":"2015","unstructured":"Paik WH, Song BJ, Kim HW, Kim HR, Hwang JH. MicroRNA-200c as a prognostic biomarker for pancreatic cancer. Korean J Gastroenterol. 2015;66:215\u201320.","journal-title":"Korean J Gastroenterol"},{"key":"3389_CR46","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.omtn.2019.06.015","volume":"17","author":"ZV Diaz-Riascos","year":"2019","unstructured":"Diaz-Riascos ZV, Ginesta MM, Fabregat J, Serrano T, Busquets J, Buscail L, et al. Expression and role of MicroRNAs from the miR-200 family in the tumor formation and metastatic propensity of pancreatic cancer. Mol Ther Nucleic Acids. 2019;17:491\u2013503.","journal-title":"Mol Ther Nucleic Acids"},{"key":"3389_CR47","doi-asserted-by":"crossref","unstructured":"Lu H, Lu S, Yang D, Zhang L, Ye J, Li M et al. MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy. Biosci Rep. 2019;39.","DOI":"10.1042\/BSR20181374"},{"key":"3389_CR48","doi-asserted-by":"publisher","unstructured":"Tarsounas M, Sung P. The antitumorigenic roles of BRCA1\u2013BARD1 in DNA repair and replication. Nat Rev Mol Cell Biol [Internet]. 2020;21:284\u201399. Available from: https:\/\/doi.org\/10.1038\/s41580-020-0218-z","DOI":"10.1038\/s41580-020-0218-z"},{"key":"3389_CR49","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s10147-017-1182-2","volume":"23","author":"M Takaoka","year":"2018","unstructured":"Takaoka M, Miki Y. BRCA1 gene: function and deficiency. Int J Clin Oncol. 2018;23:36\u201344.","journal-title":"Int J Clin Oncol"},{"key":"3389_CR50","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00018-019-03365-1","volume":"77","author":"Y Sun","year":"2020","unstructured":"Sun Y, McCorvie TJ, Yates LA, Zhang X. Structural basis of homologous recombination. Cell Mol Life Sci. 2020;77:3\u201318.","journal-title":"Cell Mol Life Sci"},{"key":"3389_CR51","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/annonc\/mdy099","volume":"29","author":"C Cruz","year":"2018","unstructured":"Cruz C, Castroviejo-Bermejo M, Guti\u00e9rrez-Enr\u00edquez S, Llop-Guevara A, Ibrahim YH, Gris-Oliver A, et al. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol. 2018;29:1203\u201310.","journal-title":"Ann Oncol"},{"key":"3389_CR52","doi-asserted-by":"publisher","unstructured":"Collins PL, Purman C, Porter SI, Nganga V, Saini A, Hayer KE et al. DNA double-strand breaks induce H2Ax phosphorylation domains in a contact-dependent manner. Nat Commun [Internet]. 2020;11:3158. Available from: https:\/\/doi.org\/10.1038\/s41467-020-16926-x","DOI":"10.1038\/s41467-020-16926-x"},{"key":"3389_CR53","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/00006676-200010000-00004","volume":"21","author":"Z Lu","year":"2000","unstructured":"Lu Z, Kleeff J, Shrikhande S, Zimmermann A, Korc M, Friess H, et al. Expression of the Multidrug-Resistance 1 (MDR1) gene and prognosis in human pancreatic cancer. Pancreas. 2000;21:240\u20137.","journal-title":"Pancreas"},{"key":"3389_CR54","doi-asserted-by":"publisher","first-page":"100409","DOI":"10.1016\/j.mcpro.2022.100409","volume":"21","author":"Q Lin","year":"2022","unstructured":"Lin Q, Shen S, Qian Z, Rasam SS, Serratore A, Jusko WJ, et al. Comparative proteomic analysis identifies key metabolic regulators of gemcitabine resistance in pancreatic cancer. Mol Cell Proteom. 2022;21:100409.","journal-title":"Mol Cell Proteom"},{"key":"3389_CR55","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3390\/cancers9110157","volume":"9","author":"M Amrutkar","year":"2017","unstructured":"Amrutkar M, Gladhaug IP. Pancreatic cancer chemoresistance to gemcitabine. Cancers (Basel). 2017;9:157.","journal-title":"Cancers (Basel)"},{"key":"3389_CR56","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41419-021-03938-8","volume":"12","author":"G Ma","year":"2021","unstructured":"Ma G, Li G, Fan W, Xu Y, Song S, Guo K, et al. Circ-0005105 activates COL11A1 by targeting miR-20a-3p to promote pancreatic ductal adenocarcinoma progression. Cell Death Dis. 2021;12:656.","journal-title":"Cell Death Dis"},{"key":"3389_CR57","doi-asserted-by":"crossref","unstructured":"Li Y, VandenBoom TG 2nd, Kong D, Wang Z, Ali S, Philip PA, et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009;69:6704\u201312.","DOI":"10.1158\/0008-5472.CAN-09-1298"},{"key":"3389_CR58","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","volume":"8","author":"H Tiriac","year":"2018","unstructured":"Tiriac H, Belleau P, Engle DD, Plenker D, Desch\u00eanes A, Somerville TDD, et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov. 2018;8:1112\u201329.","journal-title":"Cancer Discov"},{"key":"3389_CR59","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.3390\/biomedicines11092496","volume":"11","author":"J Freire","year":"2023","unstructured":"Freire J, Garc\u00eda-Berbel P, Caramelo B, Garc\u00eda-Berbel L, Ovejero VJ, Cadenas N, et al. Usefulness of COL11A1 as a prognostic marker of tumor infiltration. Biomedicines. 2023;11:2496.","journal-title":"Biomedicines"},{"key":"3389_CR60","doi-asserted-by":"publisher","first-page":"102496","DOI":"10.1016\/j.coph.2024.102496","volume":"80","author":"N Kumari","year":"2025","unstructured":"Kumari N, Kaur E, Raghavan SC, Sengupta S. Regulation of pathway choice in DNA repair after double-strand breaks. Curr Opin Pharmacol. 2025;80:102496.","journal-title":"Curr Opin Pharmacol"},{"key":"3389_CR61","doi-asserted-by":"crossref","unstructured":"Zheng R, Liu X, Zhang Y, Liu Y, Wang Y, Guo S et al. Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application. Front Immunol. 2024;15.","DOI":"10.3389\/fimmu.2024.1383978"},{"key":"3389_CR62","doi-asserted-by":"crossref","unstructured":"Raimundo L, Ramos H, Loureiro JB, Calheiros J, Saraiva L. BRCA1\/P53: Two strengths in cancer chemoprevention. Biochim Biophys Acta Rev Cancer [Internet]. 2020 [cited 2020 Jan 25];1873:188339. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31917206","DOI":"10.1016\/j.bbcan.2020.188339"},{"key":"3389_CR63","doi-asserted-by":"crossref","unstructured":"Raimundo L, Calheiros J, Saraiva L. Exploiting DNA damage repair in precision cancer therapy: BRCA1 as a prime therapeutic target. Cancers (Basel). 2021;13.","DOI":"10.3390\/cancers13143438"},{"key":"3389_CR64","doi-asserted-by":"crossref","unstructured":"Fiorini C, Cordani M, Padroni C, Blandino G, Di Agostino S, Donadelli M. Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research [Internet]. 2015;1853:89\u2013100. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0167488914003541","DOI":"10.1016\/j.bbamcr.2014.10.003"},{"key":"3389_CR65","doi-asserted-by":"publisher","first-page":"28574","DOI":"10.1074\/jbc.M404137200","volume":"279","author":"Z Feng","year":"2004","unstructured":"Feng Z, Kachnic L, Zhang J, Powell SN, Xia F. DNA damage induces p53-dependent BRCA1 nuclear export. J Biol Chem. 2004;279:28574\u201384.","journal-title":"J Biol Chem"},{"key":"3389_CR66","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ejmech.2019.01.008","volume":"165","author":"M Roberti","year":"2019","unstructured":"Roberti M, Schipani F, Bagnolini G, Milano D, Giacomini E, Falchi F, et al. Rad51\/BRCA2 disruptors inhibit homologous recombination and synergize with Olaparib in pancreatic cancer cells. Eur J Med Chem. 2019;165:80\u201392.","journal-title":"Eur J Med Chem"},{"key":"3389_CR67","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.chembiol.2021.02.006","volume":"28","author":"DE Scott","year":"2021","unstructured":"Scott DE, Francis-Newton NJ, Marsh ME, Coyne AG, Fischer G, Moschetti T, et al. A small-molecule inhibitor of the BRCA2-RAD51 interaction modulates RAD51 assembly and potentiates DNA damage-induced cell death. Cell Chem Biol. 2021;28:835\u2013e8475.","journal-title":"Cell Chem Biol"},{"key":"3389_CR68","doi-asserted-by":"publisher","unstructured":"Bagnolini G, Milano D, Manerba M, Schipani F, Ortega JA, Gioia D et al. Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib. J Med Chem [Internet]. 2020;63:2588\u2013619. Available from: https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01526","DOI":"10.1021\/acs.jmedchem.9b01526"},{"key":"3389_CR69","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nature09399","volume":"467","author":"RB Jensen","year":"2010","unstructured":"Jensen RB, Carreira A, Kowalczykowski SC. Purified human BRCA2 stimulates RAD51-mediated recombination. Nature. 2010;467:678\u201383.","journal-title":"Nature"},{"key":"3389_CR70","doi-asserted-by":"crossref","unstructured":"Prakash R, Zhang Y, Feng W, Jasin M. Homologous Recombination and Human Health: The Roles of BRCA1, BRCA2, and Associated Proteins. Cold Spring Harb Perspect Biol [Internet]. 2015 [cited 2019 Nov 3];7:a016600. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25833843","DOI":"10.1101\/cshperspect.a016600"},{"key":"3389_CR71","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.pharmthera.2016.02.003","volume":"160","author":"NS Gavande","year":"2016","unstructured":"Gavande NS, VanderVere-Carozza PS, Hinshaw HD, Jalal SI, Sears CR, Pawelczak KS, et al. DNA repair targeted therapy: the past or future of cancer treatment? Pharmacol Ther. 2016;160:65\u201383.","journal-title":"Pharmacol Ther"},{"key":"3389_CR72","doi-asserted-by":"crossref","unstructured":"Loria R, Vici P, Di Lisa FS, Soddu S, Maugeri-Sacc\u00e0 M, Bon G. Cross-Resistance among sequential cancer therapeutics: an emerging issue. Front Oncol. 2022;12.","DOI":"10.3389\/fonc.2022.877380"},{"key":"3389_CR73","doi-asserted-by":"publisher","first-page":"8482","DOI":"10.3748\/wjg.v20.i26.8482","volume":"20","author":"S Nordh","year":"2014","unstructured":"Nordh S. hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: A systematic review. World J Gastroenterol. 2014;20:8482.","journal-title":"World J Gastroenterol"},{"key":"3389_CR74","doi-asserted-by":"publisher","unstructured":"Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M et al. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer [Internet]. 2007;96:457\u201363. Available from: https:\/\/doi.org\/10.1038\/sj.bjc.6603559","DOI":"10.1038\/sj.bjc.6603559"},{"key":"3389_CR75","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1080\/00365520902745039","volume":"44","author":"R Andersson","year":"2009","unstructured":"Andersson R, Aho U, Nilsson BI, Peters GJ, Pastor-Anglada M, Rasch W, et al. Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions. Scand J Gastroenterol. 2009;44:782\u20136.","journal-title":"Scand J Gastroenterol"},{"key":"3389_CR76","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1097\/MPA.0b013e3182a23ae4","volume":"42","author":"CH Wei","year":"2013","unstructured":"Wei CH, Gorgan TR, Elashoff DA, Hines OJ, Farrell JJ, Donahue TR. A Meta-Analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers. Pancreas. 2013;42:1303\u201310.","journal-title":"Pancreas"},{"key":"3389_CR77","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jconrel.2013.03.033","volume":"169","author":"P Wonganan","year":"2013","unstructured":"Wonganan P, Lansakara-P DSP, Zhu S, Holzer M, Sandoval MA, Warthaka M, et al. Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle\u2019s ability to overcome gemcitabine resistance caused by RRM1 overexpression. J Controlled Release. 2013;169:17\u201327.","journal-title":"J Controlled Release"},{"key":"3389_CR78","doi-asserted-by":"crossref","unstructured":"Emran T, Bin, Shahriar A, Mahmud AR, Rahman T, Abir MH, Siddiquee MF-R et al. Multidrug resistance in cancer: Understanding molecular mechanisms, Immunoprevention and therapeutic approaches. Front Oncol. 2022;12.","DOI":"10.3389\/fonc.2022.891652"},{"key":"3389_CR79","doi-asserted-by":"crossref","unstructured":"Seelig A. P-Glycoprotein: one mechanism, many tasks and the consequences for pharmacotherapy of cancers. Front Oncol. 2020;10.","DOI":"10.3389\/fonc.2020.576559"},{"key":"3389_CR80","first-page":"5002","volume":"49","author":"K Yusa","year":"1989","unstructured":"Yusa K, Tsuruo T. Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-Glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562\/ADM Cells1. Cancer Res. 1989;49:5002\u20136.","journal-title":"Cancer Res"},{"key":"3389_CR81","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1111\/j.1742-4658.2011.08235.x","volume":"278","author":"Z Chen","year":"2011","unstructured":"Chen Z, Tiwari AK. Multidrug resistance proteins (MRPs\/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J. 2011;278:3226\u201345.","journal-title":"FEBS J"},{"key":"3389_CR82","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","volume":"388","author":"T Kamisawa","year":"2016","unstructured":"Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016;388:73\u201385.","journal-title":"Lancet"},{"key":"3389_CR83","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-031621-024600","volume":"18","author":"MH Sherman","year":"2023","unstructured":"Sherman MH, Beatty GL. Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance. Annu Rev Pathol. 2023;18:123\u201348.","journal-title":"Annu Rev Pathol"},{"key":"3389_CR84","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41698-024-00681-z","volume":"8","author":"Y Ju","year":"2024","unstructured":"Ju Y, Xu D, Liao M, Sun Y, Bao W, Yao F, et al. Barriers and opportunities in pancreatic cancer immunotherapy. NPJ Precis Oncol. 2024;8:199.","journal-title":"NPJ Precis Oncol"},{"key":"3389_CR85","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12929-024-01099-2","volume":"32","author":"Z Cao","year":"2025","unstructured":"Cao Z, Quazi S, Arora S, Osellame LD, Burvenich IJ, Janes PW, et al. Cancer-associated fibroblasts as therapeutic targets for cancer: advances, challenges, and future prospects. J Biomed Sci. 2025;32:7.","journal-title":"J Biomed Sci"},{"key":"3389_CR86","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3892\/ijo.2023.5499","volume":"62","author":"H Ono","year":"2023","unstructured":"Ono H, Murase Y, Yamashita H, Kato T, Asano D, Ishikawa Y, et al. RRM1 is mediated by histone acetylation through gemcitabine resistance and contributes to invasiveness and ECM remodeling in pancreatic cancer. Int J Oncol. 2023;62:51.","journal-title":"Int J Oncol"},{"key":"3389_CR87","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.matbio.2023.04.002","volume":"119","author":"A Naik","year":"2023","unstructured":"Naik A, Leask A. Tumor-associated fibrosis impairs the response to immunotherapy. Matrix Biol. 2023;119:125\u201340.","journal-title":"Matrix Biol"},{"key":"3389_CR88","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.3390\/cancers14123028","volume":"14","author":"P Gumberger","year":"2022","unstructured":"Gumberger P, Bjornsson B, Sandstr\u00f6m P, Bojmar L, Zambirinis CP. The liver Pre-Metastatic niche in pancreatic cancer: A potential opportunity for intervention. Cancers (Basel). 2022;14:3028.","journal-title":"Cancers (Basel)"},{"key":"3389_CR89","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1038\/s43018-023-00614-y","volume":"4","author":"JL Chitty","year":"2023","unstructured":"Chitty JL, Yam M, Perryman L, Parker AL, Skhinas JN, Setargew YFI, et al. A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer. Nat Cancer. 2023;4:1326\u201344.","journal-title":"Nat Cancer"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03389-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03389-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03389-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T11:02:41Z","timestamp":1745492561000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03389-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3389"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03389-5","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"27 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Integrated University Hospital Trust (Comitato Etico Azienda Ospedaliera Universitaria Integrata), University of Verona, Italy (approval number 1885) for studies with patient-derived organoids. For animal studies, all procedures were reviewed and approved by the i3S Animal Welfare and Ethics Body, and the animal protocol was approved by DGAV \u201cDire\u00e7\u00e3o Geral de Alimenta\u00e7\u00e3o e Veterin\u00e1ria\u201d.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"An international patent protecting the compound disclosed in this manuscript has been filed by the following authors: Juliana Calheiros, Silva Mulhovo, Maria Jos\u00e9 U. Ferreira, and Luc\u00edlia Saraiva. Luc\u00edlia Saraiva and Maria Jos\u00e9 U. Ferreira are co-founders of BBIT-Therapeutics, Lda.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"129"}}